Stockscreener 앱 받기
196.64
0.71%
-1.83
전일 마감가:
$198.47
열려 있는:
$198.47
하루 거래량:
243.00K
Relative Volume:
0.03
시가총액:
$340.25B
수익:
$57.37B
순이익/손실:
$4.20B
주가수익비율:
83.68
EPS:
2.35
순현금흐름:
$17.83B
1주 성능:
+2.45%
1개월 성능:
+5.40%
6개월 성능:
-2.29%
1년 성능:
+20.31%
1일 변동 폭
$196.80
$198.50
1주일 범위
$189.80
$198.98
52주 변동 폭
$153.58
$218.66
애브비 Stock (ABBV) Company Profile
명칭
Abbvie Inc
전화
(847) 932-7900
주소
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
ABBV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
196.80 | 340.25B | 57.37B | 4.20B | 17.83B | 2.35 |
|
LLY
Lilly Eli Co
|
821.37 | 739.75B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
154.99 | 370.90B | 89.33B | 21.81B | 18.57B | 8.99 |
|
NVO
Novo Nordisk Adr
|
69.44 | 277.97B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
113.66 | 222.45B | 53.22B | 12.86B | 14.85B | 6.39 |
애브비 Stock (ABBV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-12-05 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-04 | 업그레이드 | Argus | Hold → Buy |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-06-05 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-05-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-01-29 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2023-12-11 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-10-30 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-09-29 | 개시 | Raymond James | Outperform |
| 2023-07-25 | 개시 | William Blair | Mkt Perform |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-04-05 | 다운그레이드 | Argus | Buy → Hold |
| 2023-03-01 | 개시 | Guggenheim | Buy |
| 2023-02-22 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | 업그레이드 | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-11-08 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2022-08-01 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Underperform |
| 2022-05-06 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2022-02-28 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-02-03 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-03 | 재확인 | Barclays | Equal Weight |
| 2022-02-03 | 재확인 | BofA Securities | Neutral |
| 2022-02-03 | 재확인 | Goldman | Neutral |
| 2022-01-13 | 개시 | Redburn | Buy |
| 2022-01-12 | 재확인 | BMO Capital Markets | Outperform |
| 2021-12-09 | 재개 | Wells Fargo | Overweight |
| 2021-11-23 | 업그레이드 | Societe Generale | Hold → Buy |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2020-11-10 | 재개 | Bernstein | Outperform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-06-23 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | 업그레이드 | Argus | Hold → Buy |
| 2020-05-18 | 재개 | BofA/Merrill | Neutral |
| 2020-05-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-05-11 | 재개 | Morgan Stanley | Overweight |
| 2020-04-20 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2020-01-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | 재확인 | Cowen | Outperform |
| 2019-09-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-08-20 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | 개시 | Goldman | Neutral |
| 2019-04-29 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
모두보기
애브비 주식(ABBV)의 최신 뉴스
Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) Seeking Recovery for InvestorsContact The Gross Law Firm - marketscreener.com
Viral Conjunctivitis Drugs Market Overall Study Report - openPR.com
Is the Trump Administration About to Cause AbbVie, Eli Lilly, and Johnson & Johnson Stocks to Crash? - Yahoo Finance
Invest in These ETFs to Prepare Your Portfolio for a Recession - The Motley Fool
Allergan Aesthetics Boosts Women Entrepreneurs with BOTOX Cosmetic Initiative (ABBV) - GuruFocus
Fund Update: SATURNA CAPITAL CORP added 40,521 shares of ABBVIE ($ABBV) to their portfolio - Nasdaq
CERE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cerevel Therapeutics Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - TradingView
Shareholders of Cerevel Therapeutics Holdings, Inc. Should Conta - GuruFocus
Shareholders of Cerevel Therapeutics Holdings, Inc. Should Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your RightsABBV - marketscreener.com
BOTOX® Cosmetic (onabotulinumtoxinA) Continues its Mission of Empowering Entrepreneurs Through "The Confidence Project" - AbbVie News Center
AbbVie shares snap seven-session gaining streak - MSN
Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV)June 3, 2025 Deadline to Join – Contact The Gross Law Firm - TradingView
June 3, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against ABBV - marketscreener.com
PTAB Axes AbbVie Unit's Cancer Drug Patent As Invalid - Law360
Androgen Drugs Market Detailed in New Research Report By 2032 | AbbVie Inc.,Endo International plc - openPR.com
FDA approves AbbVie’s upadacitinib for giant cell arteritis - Yahoo Finance
AbbVie secures FDA approval for Rinvoq to treat giant cell arteritis - World Pharmaceutical Frontiers
In Brief: AbbVie’s Rinvoq Secures US Approval For Giant Cell Arteritis - insights.citeline.com
AbbVie Scores FDA Approval For Its Blockbuster Drug Rinvoq To Treat Type Of Arthritis - Benzinga
Why AbbVie Stock Topped the Market Today - MSN
AbbVie (NYSE:ABBV) Receives FDA Approval For RINVOQ In Treating Giant Cell Arteritis - Yahoo Finance
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years - Benzinga
Stock Of The Day: AbbVie's Rally Looks Stretched — Could A Reversal Be Next? - Benzinga
AbbVie’s Rinvoq is approved in giant cell arteritis; Relmada shares bladder cancer data - Endpoints News
AbbVie Says Rinvoq Medication Gets FDA Approval to Treat Giant Cell Arteritis - marketscreener.com
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
AbbVie (ABBV) Target Price Increased Following Strong Quarterly Results | ABBV Stock News - GuruFocus
FDA Approval for AbbVie's Rinvoq (ABBV) in Treating Giant Cell A - GuruFocus
RINVOQ® Receives U.S. FDA Approval for Giant Cell Arteritis - Investing News Network
Guggenheim Adjusts AbbVie Price Target to $216 From $214, Maintains Buy Rating - marketscreener.com
Morgan Stanley Boosts AbbVie (ABBV) Price Target to $250 | ABBV Stock News - GuruFocus
Why AbbVie Stock Trounced the Market Today - MSN
AbbVie (ABBV) Stock Rises on Positive Analyst Notes - GuruFocus
Maybe In May: US FDA Calls Coming On Moderna Next-Gen COVID-19 Vaccine, AbbVie’s Big ADC Bet - insights.citeline.com
S&P 500 Gains and Losses Today: AbbVie Stock Advances After Beat-and-Raise Earnings Report - Investopedia
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
AbbVie Immunology Portfolio Poised For Growth Through Humira Erosion: Analyst - Benzinga
AbbVie (ABBV) Target Price Raised as Confidence Grows in Long-Te - GuruFocus
AbbVie (ABBV) Sees Price Target Boost from BofA | ABBV Stock New - GuruFocus
AbbVie Stock Rises. Earnings Beat, Guidance Raised But Trump Tariffs May Bite. - Barron's
HSBC Adjusts Price Target for AbbVie (ABBV) Amid Potential Tarif - GuruFocus
AbbVie Lifts Profit Guidance as Newer Drugs Drive Sales Beat - MSN
HSBC Adjusts Price Target on AbbVie to $205 From $230, Maintains Buy Rating - marketscreener.com
AbbVie makes its tariffs-driven investment play - Pharmaphorum
AbbVie lifts profit forecast on strong sales of newer immunology drugs - MSN
Should Investors Be Worried About Dividend King AbbVie? - Nasdaq
Why AbbVie’s Stock Is A Strong Buy After Q1 2025 Results (NYSE:ABBV) - Seeking Alpha
AbbVie Stock (ABBV) Up 8% on the Week as Company Soars Past Q1 Expectations - markets.businessinsider.com
AbbVie Inc. (ABBV): Among Billionaire Ken Fisher’s Healthcare Stock Picks with Massive Upside Potential - Insider Monkey
AbbVie First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
AbbVie (ABBV) Stock: Q1 Earnings Beat and EPS Outlook Raised - CoinCentral
애브비 (ABBV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.49%
자본화:
|
볼륨(24시간):